| Molecular formula | C165H269N47O46 |
|---|
| Molecular weight | 3647.2 g/mol |
|---|
| Registered trials | 1 |
|---|
| PubChem CID | 91971820 |
|---|
What CJC-1295 is
CJC-1295 is a synthetic peptide identified in chemical databases under PubChem CID 91971820. It has a molecular formula of C165H269N47O46 and a molecular weight of approximately 3647.2. CJC-1295 does not have an FDA-approved label, and no approved brand names, indications, or mechanism-of-action statement are available for it. It is classified here as an unapproved research compound rather than an approved medicine.
Trial footprint
One trial involving CJC-1295 is registered in the available clinical trials data. That study, NCT00267527, examined CJC-1295 in HIV patients with visceral obesity and reached Phase 2 before its status was recorded as terminated. No other trial records or adverse event report data are available for this compound in the dataset reviewed.
FAQ
No. CJC-1295 has no FDA-approved label, indication, or brand name. It is classified as an unapproved research compound based on the available data.
CJC-1295 is a synthetic peptide with the molecular formula C165H269N47O46 and a molecular weight of about 3647.2. It is catalogued in PubChem under CID 91971820.
One registered clinical trial involving CJC-1295 has been identified, NCT00267527, which examined its use in HIV patients with visceral obesity. That trial reached Phase 2 and was later terminated.
The available data indicates the trial reached Phase 2 status before being terminated. No outcome or efficacy data from this trial is included in the dataset reviewed.
No adverse event report data is available for CJC-1295 in the dataset reviewed, so no side effect pattern can be summarized at this time.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19